



## Toll-like-Receptor and Takeda-G-Protein-Receptor-5 Interplay in Immunomodulation of Inflammatory Colorectal Cancer and Cholangiocarcinomas: Cancer-Immunotherapy Snapshot

**Saumya Pandey**

M. Sc. Biochemistry, Ph.D. Life Science, Post-Doctoral Fellowship: Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas/Doctoral Research Fellowship: Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska/Visiting Scientist-Clinical Observer: Urology, New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and Head Department of Clinical Research, IndiraIVF Hospital, Udaipur/Lucknow, India (Formerly)

### Article Info

**Received:** August 07, 2024

**Accepted:** August 19, 2024

**Published:** September 04, 2024

**\*Corresponding author:** Saumya Pandey, M. Sc. Biochemistry, Ph.D. Life Science, Post-Doctoral Fellowship: Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas/Doctoral Research Fellowship: Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska/Visiting Scientist-Clinical Observer: Urology, New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and Head Department of Clinical Research, IndiraIVF Hospital, Udaipur/Lucknow, India (Formerly).

**Citation:** Saumya Pandey. (2024) "Toll-like-Receptor and Takeda-G-Protein-Receptor-5 Interplay in Immunomodulation of Inflammatory Colorectal Cancer and Cholangiocarcinomas: Cancer-Immunotherapy Snapshot.", *J of Gastroenterology and Hepatology Research*, 5(2); DOI: 10.61148/2836-2888/GHR/051.

**Copyright:** ©2024 Saumya Pandey. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Dissecting the cellular/molecular/genetic regulatory biochemical immune-inflammatory signaling networks, primarily Toll-like-Receptor and Takeda-G-Protein-Receptor-5 intersections in "gastrohepatic disease-web" primarily colorectal/cholangio-carcinomas, is essential for diminishing the disproportionate share of morbidities and mortalities in susceptible "at-risk" American cohorts of Texas, Nebraska and New York states in USA and Indian cohorts in Asia-Pacific region for eventual design of promising evidence-based patient-friendly cost-effective predictive and prognostic biomarkers and/or pharmacological scaffolds for future immunotherapeutically potent drugs with minimal adverse effects in the post-Covid-19/Omicron global pandemic and vaccination era.

Aberrant "metabolic-flux" in the hypoxic/vascular-insufficient/inflammatory heterogeneous tumour-core infiltrated with proliferative and/or necrotic/apoptotic/autophagic cells of distinct phenotypes, is a major hallmark of gastro-hepatic-cancers [3]; therapeutic targeting of "immunogenic cell-death cascade(s)" viz. autophagy-necrosis-apoptosis, offers fascinating avenues for future stem cells'-translational research in the Covid-19 pandemic era.

Pandey [1,2,4] has elegantly emphasized the significance of age-/ethnicity-matched disease-free controls from the general random population in multi-centric epidemiology/ pharmacogenetics/genomics studies for demystifying the cellular/molecular/genetic basis of inflammatory gastro-hepatic ailments in susceptible cohorts. Moreover, receptor-based heterogeneity of ghrelin is indeed intriguing wherein a single ghrelin receptor and/or interrelated co-receptor may have differential binding affinity, leading to altered metabolic flux in the host cell and tissue in aberrant physiologic milieu in the inflammatory gastric epithelium.

Future multi-centric large sample size-based case-control prospective studies adhering to core tenets of good practice ethical research with long-term patient satisfaction trends are warranted for precision-based novel Toll-like-Receptor and Takeda-G-Protein-Receptor-5 immunotherapeutics in colorectal/cholangio-carcinomas.

### Conflicts of interest:

The author declares that she has no conflicts of interest and financial disclosures.

## References:

1. Pandey S, Agrawal DK. Immunobiology of Toll-like Receptors: Emerging trends. *Immunology and Cell Biology* 2006; 84(4):333-341.
2. Pandey S. Re: Takeda-G Protein Receptor-5 signaling mitigates parenteral nutrition-associated liver disease: Public health impact. *American Journal of Physiology Gastrointestinal Liver Physiology* 2020; 318(5):G928-G929.
3. Kouroumalis E, Tsomidis I, Voumvouraki A. Interplay of autophagy, apoptosis, and senescence in primary biliary cholangitis. *Explor Dig Dis.* 2023;2:223–45.
4. Pandey S. Letter to Editor: Healthy Controls in Non-Alcoholic Fatty Liver Disease Management: a Biomedical Research Perspective. *Hepatology* 2017; 66(3):1006-1007.